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Abstract To determine whether IDH1 mutations are present
in primary and relapsed (local and distal) conventional central
chondrosarcomas; and secondly, to assess if loss of p16/
CDKN2A is associated with tumour grade progression, 102
tumour samples from 37 patients, including material from
presenting and relapse events, were assessed. All wild-type
cases for IDH1 R132 substitutions were also tested for IDH2
R172 and R140 alterations. The primary tumour and the most
recent relapse sample were tested for p16/CDKN2A by inter-
phase fluorescence in situ hybridisation. An additional 120
central cartilaginous tumours from different patients were also
tested for p16/CDKN2A copy number. The study shows that if
an IDH1 mutation were detected in a primary central
chondrosarcoma, it is always detected at the time of presenta-
tion, and the same mutation is detected in local recurrences
and metastatic events. We show that p16/CDKN2A copy
number variation occurs subsequent to the IDH1 mutation,
and confirm that p16/CDKN2A copy number variation occurs
in 75% of high grade central chondrosarcomas, and not in low
grade cartilaginous tumours. Finally, p16/CDKN2A copy
number variation is seen in both the IDH1 wild-type and
mutant cartilaginous central tumours.
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Introduction
Isocitrate dehydrogenase 1 (IDH1), and IDH2mutations were
originally reported as frequent events in gliomas and acute
myeloid leukaemia. We subsequently revealed the presence
of the same mutations in at least 56 % of central
chondrosarcomas: the mutations are present in all grades and
the dedifferentiated variant but not in the other subtypes
(peripheral and clear cell chondrosarcoma), or in soft tissue
tumours [1, 6]. The mutations are also present in
enchondromas, the benign central cartilaginous tumour con-
sidered to represent the precursor of central chondrosarcoma,
and occur as early post-zygotic events in the common forms of
multiple enchondromas, namely Ollier disease and Maffucci
syndrome [3, 9]. These findings make a case for IDH1/2
mutations occurring early in the development of the non-
syndromic disease and that the mutations represent driver
mutations, to which the tumours are addicted for survival.
Nevertheless, to provide further evidence for this, we now
evaluate if the mutations always occur in the presenting tu-
mour, and if they persist in recurrent and metastatic disease.
This is an important question if drugs, which may be devel-
oped against the mutant protein, are to be effective [10].
Disease progression in IDH1/2 mutant-bearing tumours is
likely to depend on additional contributing genetic events.
Loss of copy number of p16/CDKN2A is a well recognised
tumour suppressor gene involved in cancer oncogenic pro-
cess, and has been reported to be associated with disease
progression of cartilaginous tumours. Specifically, p16/
CDKN2A has been found to occur in high grade
chondrosarcomas but rarely in chondrosarcoma grade (G) I
and not in enchondromas [5, 13]. Furthermore, we
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subsequently revealed that homozygous p16/CDKN2A dele-
tions were only detected in high grade chondrosarcomas (GII,
GIII and dedifferentiated) but not in GI central tumours, and
that these genetics alterations were detected in both IDH1
mutant and wild-type (WT) central chondrosarcomas [12].
Therefore, we wished to determine if loss of p16/CDKN2A
in relapse disease correlates with progression to a higher grade
of tumour.
Material and methods
One hundred and two samples from 37 patients, with the
associated demographic data, and the interval between the
primary tumour and first relapse event, were retrieved from
the files of the Royal National Orthopaedic Hospital NHS
Trust. Haematoxylin and eosin-stained sections from all se-
lected tumours were reviewed (MFA, AMF, RT). Age and
gender of the 37 patients with their tumour grade are shown in
Table 1.
An additional 120 central conventional cartilaginous tu-
mours from our previous IDH study were analysed for p16/
CDKN2A copy number [1]. This cohort included 61 low grade
cartilaginous tumours (enchondromas and chondrosarcomas
GI), 2 chondrosarcomas GI with transition to GII, 30
chondrosarcomas GII, 6 chondrosarcomas GIII and 21
dedifferentiated chondrosarcomas.
Genomic DNA was extracted from material that was at
least 60 % tumour-rich and was analysed using PCR amplifi-
cation followed by capillary sequencing and/or realtime PCR
as previously described [1]. Sections from the primary tumour
and the most recent recurrence were analysed by fluorescence
in situ hybridisation (FISH) for p16/CDKN2A (9p21) using
commercially available probes (Vysis, Abbott Molecular,
Illinois USA) as previously described [2]. Loss of p16/
CDKN2A was defined as: (i) monosomy (1 p16/CDKN2A
and 1 centromeric signal); (ii) heterozygous deletion (loss of
1 copy of p16/CDKN2A in the presence of 2 centromeric
signals) and (iii) homozygous deletion (loss of 2 copies of
p16/CDKN2A in the presence of 1 or 2 centromeric signals) in
at least 15 % of the nuclei analysed (minimum count of 50
consecutive non-overlapping nuclei). Polysomy was defined
as more than 2 copies of p16/CDKN2A/CEP 9 in at least 15 %
of the nuclei analysed.
Results
One hundred and two tumour samples from 37 patients were
analysed for IDH1 R132 of which 48 (49 %) were found to
harbour a R132 IDH1 mutation. Thirty of these 48 tumours
represented disease from relapse events (27 local recurrences
and 3 metastatic events). An IDH1 mutation was detected in
the presenting and relapse samples from each of these 18
patients. All samples from a given patient in this group had
the same IDH1 alteration (Fig. 1a.). If a tumour at presentation
was found to be wild-type (WT) for IDH1 R132 mutations,
the relapse samples were also WT (19/37 patients). In IDH1
WT cases, at least 1 sample, from each of these patients, was
also screened for both IDH2 R172 and R140 mutations. No
IDH2 (R172 or R140) mutations were detected in this cohort.
Details of the interval between the primary treatment (cu-
rettage or wide excision) of the presenting tumour and the first
recurrence is given in Table 1. The number of relapse events
per patient ranged from 1 to 5 (average 1.9).
Analysis of the p16/CDKN2A gene locus by FISH gave
informative results from both the primary tumour and the most
recent relapse in 31 of the 37 patients. In contrast to the
persistent presence of IDH1 mutations throughout tumour
progression, p16/CDKN2A copy number variation only oc-
curred in high grade chondrosarcomas (GII, GIII or
dedifferentiated neoplasms). Of the 21 tumour sets (from 31
informative cases) in which p16/CDKN2A copy number var-
iation was identified in either the primary and/or relapse event,
11 harboured an IDH1 mutation and 10 were WT for IDH1
and IDH2, indicating that change in p16/CDKN2A copy num-
ber is equally common in IDH1 mutant and WT central
conventional cartilaginous tumours.
Of the 31 informative tumour sets, 23 revealed the same
p16/CDKN2A copy number in both samples, and 8 had dis-
cordant copy number (vide infra). The former included 10
with normal copy number of p16/CDKN2A, 10 with loss of
p16/CDKN2A, and 3 with polysomy for chromosome 9. In
only 2 of these tumour sets did the grade of the tumour
progress; in both cases from GII to GIII, both with normal
copy number of p16/CDKN2A (Table 1). There were only 2
chondrosarcoma GI which recurred, 1 was non-informative
for FISH, and the other revealed a normal copy number of
p16/CDKN2A. Within this group, the samples from patient 30
were particularly noteworthy in that, the presenting tumour
was a dedifferentiated chondrosarcoma in which the normal
(diploid) p16/CDKN2A copy number was detected in the
well-differentiated component (Fig. 1. b1; Table 1) and a
homozygous dele t ion was detec ted in both the
dedifferentiated component of the presenting and the metasta-
tic tumour (Fig. 1. b2).
Of the 8 sample sets from the 31 patients which revealed
discordant p16/CDKN2A copy number, loss of p16/CDKN2A
was observed in the relapse event and not in the primary
tumour in 5 cases (3 of which also harboured IDH1mutation).
In tumours from 2 patients, polyploidy of chromosome 9 was
observed in the relapse event whereas in the primary tumour,
the normal copy number was seen in 1 case and monosomy in
the other. In the remaining case, loss of p16/CDKN2A con-
verted from being heterozygous in the primary tumour to
being homozygous in the relapse sample. In 4/8 (50 %) of
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these patients, progression of the chondrosarcoma grade oc-
curred in the relapse. In 3, the primary tumour showed normal
copy number, and progression to a higher morphological
grade (GII to GIII) was accompanied by p16/CDKN2A loss.
The fourth tumour which presented as a chondrosarcoma GII
was monosomic for chromosome 9 and progressed to a
dedifferentiated tumour, in which the tumour cells were
polysomic for chromosome 9.
The additional 120 central conventional cartilaginous tu-
mours from 120 different patients were analysed for p16/
CDKN2A by FISH. Of the 61 low grade tumours, all revealed
normal diploid p16/CDKN2A copy number. Loss of p16/
CDKN2A was detected in 25 % (8/30) of the CHS GII,
including 2 cases diagnosed as GI with transition to GII, and
50 % of the CHS GIII (3/6). The 62 % of the dedifferentiated
chondrosarcomas (13/21) also revealed p16/CDKN2A loss.
Table 1 Characteristics of 37 patients with multiple samples
Case Age Gender Site primary Number of samples Grade primary Grade relapses IDH1 status CDKN2A/p16 Interval from primary
to 1st relapse (months)
1 32 female sacrum 3 G2 G2 WT loss > further loss 31
2 80 male femur 4 Dediff Dediff R132H normal > loss 24
3 35 male pelvis 2 G2 G2 WT loss 51
4 50 male vertebra 3 G2 G2 WT NI 102
5 69 female rib 4 G2/3 G2/3 WT NI 15
6 41 female sternum 2 G2 G3 WT normal 101
7 39 female tibia 2 G2 G2 WT normal 88
8 57 male rib 4 G2 G2 R132C normal 8
9 30 male scapula 2 G2 Dediff WT loss > polysomic 17
10 41 male vertebra 3 G3 G3 WT loss 27
11 44 male pelvis 3 G3 G3 R132G polysomic 19
12 22 male sacrum 3 G2 G2 WT loss 12
13 51 male humerus 3 G3 G3 WT normal > polysomic 9
14 74 male femur 2 G2 G2 R132G loss 38
15 42 female hand 2 G2 G2 R132S NI 67
16 39 male humerus 3 G2 G3 R132C normal > loss 15
17 43 male femur 2 G2 G2 R132C normal 57
18 64 female tibia 3 G1 G1 WT NI 14
19 55 male hand 6 G2 G3 R132G normal 15
20 28 female pelvis 2 G2 G2 WT loss 34
21 31 male scapula 5 G2 G3 WT normal > loss 15
22 69 female femur 3 G2 G3 R132G NI 13
23 43 male vertebra 4 G2 G2 WT normal 11
24 34 male humerus 2 G2 G3 WT normal > loss 16
25 50 male humerus 3 G3 G3 WT loss 12
26 77 male tibia 2 G3 G3 R132L loss 33
27 72 male femur 2 Dediff Dediff R132H loss 6
28 58 female sacrum 2 G2 G2 WT normal 27
29 36 female humerus 2 G1 G1 R132C normal 15
30 51 male femur 3 Dediff Dediff R132H loss 5
31 52 male pelvis 2 Dediff Dediff R132C polysomic 12
32 55 male femur 2 Dediff Dediff R132G loss 4
33 30 female tibia 3 G2 G2 WT normal 48
34 68 male femur 2 Dediff Dediff R132S polysomic 1
35 61 male femur 2 G2 G2 R132H normal > loss 23
36 65 male rib 2 G2 Dediff WT NI 26
37 29 female femur 3 G2 G2 R132C normal 127
G grade, Dediff dedifferentiated chondrosarcomas, WTwild-type
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Polysomy of p16/CDKN2Awas detected in 2/30 GII, 1/6 GIII
and 6/21 dedifferentiated chondrosarcomas.
Further analysis of 3/21 dedifferentiated chondrosarcomas
where material was available/suitable for analysis, there was
normal diploid p16/CDKN2A copy number in the well-
differentiated component and p16/CDKN2A loss in the
dedifferentiated component.
Discussion
In this study, we confirm the data published in our previous
report showing that IDH1 mutations occur in ∼50 % of
solitary conventional central chondrosarcomas, that the
IDH1 mutations are found in all grades of this subtype of
chondrosarcoma, that the R132C mutation is the most com-
mon genetic alteration in this gene, that IDH2 mutations are
significantly less common than IDH1 mutations and that to
date an IDH2 R140 mutation, which is seen in acute myeloid
leukaemia, is not found in cartilaginous tumours [1]. In addi-
tion, we now show that when an IDH1mutation is present in a
solitary primary central conventional chondrosarcoma, the
same mutation is always detected in local recurrences and
metastatic events. Furthermore, a mutation is never detected
in a locally recurrent tumour or metastatic lesion when it is not
detected in the presenting tumour. These data add weight to
existing evidence that the R132 IDH1mutations occur early in
the genesis of cartilaginous tumours and are therefore impor-
tant driver alterations. This provides a strong argument that
the cartilaginous tumours harbouring the genetically altered
IDH1 are good candidates for the selective inhibitors of the
metabolic enzyme, IDH1 [10].
Although IDH1/IDH2mutations appear to be an important
genetic event in the pathogenesis of enchondromas and central
chondrosarcomas, other mutations are likely to exert an im-
pact on the biological behaviour of the disease. To date, two
important tumour suppressor genes, p16/CDKN2A and TP53
have been implicated in the development of high grade
chondrosarcoma [5, 11, 12]. Genetic alterations of both of
these genes have been de tec t ed prev ious ly in
chondrosarcomas [4, 5, 12]. In the case of TP53, inactivation
has been shown to occur as a result of chromosomal loss and
point mutations, and TP53 mutations have been detected in
both IDH1WT and mutant chondrosarcomas [8, 12]. Herein,
we demonstrate that alteration in p16/CDKN2A copy number
occurs exclusively in high grade central cartilaginous
Fig. 1 a Case 22 showing the primary (A.1.a) excision of a
chondrosarcoma GII, (A.1.b) harbouring a R132G substitution (A.1.c)
and 2 subsequent relapse events in the chest wall (A.2.a, A.2.b and A.3). b
Case 30. Diploid p16/CDKN2A copy number (B1) and heterozygous loss
of p16/CDKN2A (B2)
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tumours, and that the percentage of cases with alteration of
copy number of p16/CDKN2A increases with grade.
Specifically, we show that 75% (67 tumours from 89 patients)
of central high grade chondrosarcomas reveal loss or gain
(polysomy) of p16/CDKN2A in at least one sample (data
generated from both cohorts). We also show that loss of p16/
CDKN2A is found in both IDH1WTand mutant cartilaginous
central tumours, indicating that the two genetic events are
unrelated.
We consider that our findings support the concept that
alteration of p16/CDKN2A copy number occurs subsequent
to the acquisition of the IDH1 mutation. This is supported
by our findings that in 60 low grade central conventional
tumours (enchondroma/low grade chondrosarcoma), ob-
tained from patients with a single tumour sample, none
had p16/CDKN2A copy number variation. This concurs
with previously published data from smaller cohorts which
report that loss of p16/CDKN2A is rarely present in
enchondromas and low grade chondrosarcomas, whereas
IDH1 and IDH2 mutations are found in tumours of all
grades of chondrosarcomas and in benign conventional
central cartilaginous tumours [12, 13]. Our findings indi-
cate that if a tumour shows p16/CDKN2A copy number
variation (gain or loss), it should be managed as a high
grade chondrosarcoma. As grading of chondrosarcoma has
been shown to lack reproducibility [7] assessment of alter-
ation in copy number of p16/CDKN2A can be used to
complement histological grading of chondrosarcoma. The
presence of alteration in copy number argues strongly for a
diagnosis of high grade disease, although the absence of
such abnormality is not helpful as such changes are detect-
ed in ∼75 % of high grade chondrosarcoma. Future studies
would be helpful to identify a biomarker to distinguish the
remaining 25 % of high grade chondrosarcomas from low
grade disease.
We conclude that IDH1 mutations represent a recur-
rent genetic event in solitary central chondrosarcomas,
that they occur early in disease development and persist
during tumour recurrence and metastatic disease thereby
adding to the existing evidence that such mutations
represent drivers of disease. The p16/CDKN2A copy
number variation occurs in at least 50 % of IDH1
mutant-bearing high grade chondrosarcomas, and the
findings support the concept that the p16/CDKN2A al-
terations are likely to be associated with disease pro-
gression. Assessment of p16/CDKN2A copy number can
be used as an ancillary test to help reach a conclusion
about the grade of a chondrosarcoma thereby providing
additional information on which to decide clinical man-
agement of this disease.
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